#None #Washington, DC #Hemab Therapeutics #Glanzmann Thrombasthenia #Sutacimig

Hemab Therapeutics Highlights Groundbreaking Advances at ISTH 2025 Congress

On June 10, 2025, Hemab Therapeutics announced a notable line-up of presentations showcasing their latest clinical and preclinical advancements in the treatment of serious bleeding disorders. Scheduled to take place at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress in Washington, D.C., these presentations aim to shed light on innovative therapeutic options aimed at addressing significant unmet medical needs in patients suffering from disorders like Glanzmann thrombasthenia and Von Willebrand disease.

Focus on Groundbreaking Treatments

Among the highlights is Sutacimig (formerly known as HMB-001), a promising investigational drug that continues to display outstanding interim results in its Phase 2 trials. This treatment has recently received its International Non-Proprietary Name (INN) designation by the World Health Organization, further legitimizing its potential as a leading therapeutic option for Glanzmann thrombasthenia (GT), a serious inherited bleeding disorder characterized by a lack of platelet aggregation, resulting in severe bleeding episodes.

CEO Benny Sorensen, MD, PhD, expressed excitement about the participation in ISTH 2025, saying, "Our latest results from the sutacimig Phase 2 study and encouraging new clinical data from our HMB-002 program demonstrate our commitment to transformative therapies for patients with underserved diseases. Listening to and understanding patient experiences are fundamental to Hemab’s mission, and we are eager to present data that highlight the lived experiences of patients."

Promising Data on HMB-002

Further alongside Sutacimig, Hemab is excited to introduce HMB-002, which is demonstrating potential in treating Von Willebrand disease through initial proof of mechanism data collected from ongoing trials. This innovative treatment aims to directly address the defects associated with Von Willebrand Factor (VWF), an essential component for proper platelet functioning and hemostasis.

With preliminary results indicating a favorable safety profile and promising treatment effects, HMB-002 may revolutionize how practitioners approach this condition where existing management options often fall short of addressing the underlying causes.

Addressing Unmet Needs

The soft underbelly of the treatment landscape for serious bleeding disorders is evident with Glanzmann thrombasthenia, where a recent global study revealed that 88% of participants experienced at least one bleeding episode in the previous week. This situation starkly highlights the critical need for effective prophylactic treatments, especially considering that many patients reported substantial impacts on their daily lives, ranging from emotional distress to social isolation due to the unpredictability and severity of their symptoms.

In collaboration with the ISTH conference, Hemab Therapeutics will share comprehensive insights gathered from natural history studies, showcasing the burden of these conditions and furthering the need for modern treatments. These insights will aid healthcare providers and researchers in understanding the trajectory of these disorders and how Hemab's innovations can mitigate such challenges.

Future Directions and Commitment

In essence, Hemab Therapeutics’ commitment goes beyond just releasing data; it's about transforming the treatment landscape for detrimental bleeding disorders. With a strong pipeline of investigational therapies that target both immediate treatment and the root causes of these bleeding disorders, Hemab is not only focused on symptom management but also on providing tangible improvements in quality of life for patients.

The presence at ISTH 2025 exemplifies Hemab's dedication to advancing healthcare solutions aimed at individuals with high unmet needs in the bleeding disorder community. By partnering with industry experts and engaging the wider community, Hemab aims to redefine care options, ensuring individuals living with bleeding disorders receive the attention and innovative treatments they deserve.

To explore more about Hemab’s current and future developments, details about ongoing clinical trials can be found at clinicaltrials.gov.

Conclusion

As the ISTH 2025 Congress approaches, anticipation builds around Hemab Therapeutics’ presentations, particularly among healthcare professionals eager to enhance their understanding and management of bleeding disorders. With groundbreaking data soon to be revealed, stakeholders can expect a significant shift in the conversation surrounding these conditions and further commitment to improving patient outcomes.